LAVAL, Que. - Valeant Pharmaceuticals International, Inc. (TSX:VRX) has a deal to sell its Obagi skin care business to a Hong Kong-based group for US$190 million in cash.
The Quebec-based company, headquartered in Laval, estimates its Obagi Medical Products unit will generate about US$85 million of revenue in 2017.
The buyer is a fund managed by a limited partnership that includes China Regenerative Medicine International and Haitong International Securities Group, both headquartered in Hong Kong.
Bagikan Berita Ini
Related Posts :
Major Canadian canola exporter to China says finding new markets not easy- Chinese woman carrying malware allegedly got into Trump's Mar-a-Lago resort
- Malaysia to sell yacht at centre of 1MDB scandal for US$126M
- Asian shares edge higher ahead of U.S.-China trade talks
- Malaysian ex-PM Najib attends 1st day of graft trial
0 Response to "Valeant to sell Obagi skin-care business for US$190M"
Post a Comment